Icahn increases Biogen Idec stake
This article was originally published in Scrip
Executive Summary
Carl Icahn has turned his attentions from ImClone Systemsand its approach by Bristol-Myers Squibb back towards Biogen Idec,increasing his stake in the US company after its stock fell earlier this month following the re-emergence of safety concerns for Tysabri (natalizumab).